Management of malignant pleural effusions

European Respiratory Journal

Volumn 18, Issue 2, 2001, Pages 402-419

  Antony, V B ^a   Loddenkemper, R ^a   Astoul, P ^a   Boutin, C ^a   Goldstraw, P ^a   Hott, J ^a   Rodriguez Panadero, F ^a   Sahn, S A ^a  

^a Lungenklinik Heekeshorn   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXYCYCLINE; GAMMA INTERFERON; INTERLEUKIN 2; METHOTREXATE; MITOMYCIN; PROCARBAZINE; TALC; TETRACYCLINE;

BREAST CARCINOMA; BRONCHOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEVER; HUMAN; LEUKEMIA; LUNG CARCINOMA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MESOTHELIOMA; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PLEURA BIOPSY; PLEURA EFFUSION; PLEURODESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYMPTOM; THORACOCENTESIS; THORACOSCOPY; THORAX PAIN; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; BIOPSY; BRONCHOSCOPY; GENE THERAPY; HUMANS; PLEURAL EFFUSION, MALIGNANT; PLEURODESIS; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TALC;

EID: 0034886125     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.01.00225601     Document Type: Review

References (211)

1. Pleural metastatic tumours and effusions: Frequency and pathogenic mechanisms in a post-mortem series
2. Primary carcinoma of the lung: A review of 417 histologically proved cases
3. The natural history of carcinoma of the lung
4. Breast cancer complicated by pleural effusion
5. Breast cancer and thoracic metastasis: Review of 119 patients
6. Pathogenesis of pleural effusion in carcinoma of the breast
7. Pleural effusion in lymphoma
8. Metastatic pattern at autopsy in non-resectable adenocarcinoma of the lung
9. Metastatic pattern in adenocarcinoma of the lung
10. Breast carcinoma: Pattern of metastasis at autopsy
11. Intrathoracic manifestations of the lymphomatoid diseases
12. Carcinomatous involvement of the pleura: An analysis of 96 patients
13. The malignant pleural effusion: A review of cytopathological diagnoses of 584 specimens from 472 consecutive patients
14. Cytologic detection of malignancy in pleural effusion: A review of 5,255 samples from 3,811 patients
15. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusions: Analysis of 414 cases
16. The interval between the diagnosis of malignancy and the development of effusions, with reference to the role of cytologic diagnosis
17. Cancer statistics 1997
18. The incidence of pleural effusion in a well-defined region: Epidemiologic study in central Bohemia
19. The aetiology of pleural effusions in an area with high incidence of tuberculosis
20. Metastatic carcinoma of the pleura
21. The role of immune complexes in the pathogenesis of pleural effusions
22. Pleural diseases related to metastatic malignancies
23. Mechanism of relief of dyspnoea after thoracentesis in patients with large pleural effusions
24. Diagnosis and prognostic factors in malignant pleural mesothelioma: A retrospective analysis of sixty-five patients
25. Massive pleural effusions: Malignant and nonmalignant causes in 46 patients
26. Pleural changes in malignant pleural effusions: Appearance on computed tomography
27. Complications associated with thoracentesis: A prospective randomized study comparing three different methods
28. Malignant pleural mesothelioma: Value of CT and MRI imaging in predicting resectability
29. MR imaging to detect chest wall and pleural involvement in patients with lymphoma: Effect on radiation therapy planning
30. Magnetic resonance (MR) imaging of the chest: State of the art
31. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography
32. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities
33. Pleural effusions: The separation of transudates and exudates
34. Diagnostic value of tests that discriminate between exudative and transudative pleural effusions
35. Relationship between cell type, glucose concentration, and response to treatment in neoplastic effusions
36. The serum-effusion albumin gradient in the evaluation of pleural effusions
37. Cells in pleural fluid: Their value in differential diagnosis
38. Diagnostic significance of lymphocytes in pleural effusions
39. Diagnostic utility of pleural eosinophilia
40. Aetiology and prognostic significance of eosinophilic pleural effusions
41. Pleural fluid pH in malignant effusions: Diagnostic, prognostic, and therapeutic implications
42. Survival and talc pleurodesis in metastatic pleural carcinoma, revisited
43. Low glucose and pH levels in malignant effusions; diagnostic significance and prognostic value in respect to pleurodesis
44. The pathogenesis of low glucose, low pH malignant effusions
45. Survival time of patients with pleural metastatic carcinoma predicted by glucose and pH studies
46. Malignant pleural effusions: Meaning of pleural-fluid pH determination
47. Intrapleural Corynebacterium parvum for recurrent malignant pleural effusions
48. Malignant pleural effusions: Prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases
49. Thoracoscopic talc poudrage in malignant pleural effusions: Effective pleurodesis despite low pleural pH
50. Corynebacterium parvam pleurodesis and survival is not significantly influenced by pleural pH and glucose level
51. Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions
52. Pleural fluid pH as a predictor of pleurodesis failure
53. Predicting survival in patients with recurrent symptomatic malignant pleural effusions
54. A prospective study of amylase-rich pleural effusions with special reference to amylase isoenzyme analysis
55. High amylase in neoplasm-related pleural effusion
56. Hyaluronan in pleural effusions and in serum
57. The value of multiple preparations in the diagnosis of malignant pleural effusions
58. Prospective evaluation of biopsy methods in the diagnosis of malignant pleural effusions: Intrapatient comparison between pleural fluid cytology, blind needle biopsy and thoracoscopy
59. Diagnostic value of DNA analysis in effusions by flow cytometry and image analysis
60. Cheromosome analysis in pleural effusions: Efficiency of this method in the differential diagnosis of pleural effusions
61. Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma
62. Markers for metastatic adenocarcinoma in serous effusion specimens
63. Significance of epithelial membrane antigen in the work-up of problematic serous effusions
64. Identification of carcinoma cells in ascitic and pleural fluid: Comparison of four panepithelial antigens with carcinoembryonic antigen
65. Assessment of immunocytochemical and histochemical stainings in the distinction between reactive mesothelial cells and adenocarcinoma cells in body effusions
66. Immunocytochemical staining of cells in pleural and peritoneal effusions with a panel of monoclonal antibodies
67. Immunocytochemical differentiation of reactive mesothelial cells and adenocinoma cells in serous effusions with the use of CEA and fibronectin
68. Monoclonal antibody Ber-EP4: Its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens
69. Immunocytochemistry and ELISA quantitation of muan for diagnosis of malignant pleural effusions
70. Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3-a new tumor marker
71. Lung surfactant protein-A and CEA in pleural effusions due to lung adenocarcinoma and malignant mesothelioma
72. Sensitivity, specificity, and predictive values of closed pleural biopsy
73. Cytological and bacteriologic analysis of fluid and pleural biopsy specimens with Cope's needle
74. The role of closed pleural needle biopsy in the diagnosis of malignant mesothelioma of the pleura
75. Points to consider when choosing a biopsy method in cases of pleurisy of unknown ongin
76. Thoracentesis and pleural biopsy
77. Thoracoscopy: Diagnostic and therapeutic indications
78. The diagnostic and therapeutic utility of thoracoscopy: A review
79. Thoracoscopy-State of the art
80. Thoracoscopy in malignant pleural effusions
81. Thoracoscopy: A safe accurate diagnostic procedure using the rigid thoracoscope and local anesthesia
82. Thoracoscopy for the diagnosis of pleural disease
83. Thoracoscopy in the diagnosis of pleural effusions
84. Practical thoracoscopy
85. Pleuroscopy in clinical evaluation and staging of lung cancer
86. Lung cancer and pleural effusion: Clinical significance and study of pleural metastatic locations
87. The so-called malignant pleural effusion: A new review of direct data obtained with diagnostic pleuroscopy
88. Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 1: Diagnosis
89. Thoracoscopy in pleural malignant mesothelioma: Part 2. Prognosis and staging
90. A proposed new international TNM staging system for malignant pleural mesothelioma
91. Malignant pleural mesothelioma
92. Black spots concentrate oncogenic asbestosis fibers in the parietal pleura: Thoracoscopic and mineralogic study
93. Pleural effusion in breast cancer: Thoracoscopy for hommone receptor determination
94. Pleural effusion in non-Hodgkins lymphoma
95. Thoracoscopy: Results in noncancerous and idiopathic pleural effusions
96. Differentiation between malignant and nonmalignant pleural effusion
97. Pleural effusion: A diagnostic dilemma
98. Pleural effusion: Laboratory tests in 300 cases
99. Evaluation des moyens diagnostiques dans les epanchements pleuraux
100. The outcome of patients with pleural effusion of indetemminate cause at thoracotomy
101. Fibreoptic bronchoscopy in the management of lone pleural effusion: A negative study
102. Fiberoptic bronchoscopy and pleural effusion of unknown origin
103. Use of fiberoptic bronchoscopy in the diagnosis of bronchogenic carcinoma: A study in patients with idiopathic pleural effusions
104. Statement of the AATS/STS Joint Committee on thoracoscopic and video-assisted thoracic surgery
105. Observations on pleural pressures as fluid is withdrawn during thoracentesis
106. Elastance of the pleural space: A predictor for the outcome of pleurodesis in patients with malignant pleural effusion
107. Effects of acute pleural effusion on respiratory system mechanics in dogs
108. The relationship between pleural pressures and changes in pulmonary function after therapeutic thoracentesis
109. Effects of thoracentesis on pulmonary gas exchange
110. Effect of thoracentesis on arsenal oxygen tension
111. Hypoxaemia after thoracentesis: A predictable and treatable condition
112. Changes in pulmonary mechanics and gas exchange following thoracentesis
113. Evidence for increased permeability in re-expansion pulmonary oedema
114. Chemical pleurodesis for malignant pleural effusions
115. Comparison of intracavitary bleomycin and talc for the control of pleural effusions secondary to carcinoma of the breast
116. Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions
117. A comparison of intracavitary talc and tetracycline for the control of pleural effusions secondary to breast cancer
118. Pleurodesis using talc slurry
119. Sclerotherapy for malignant pleural effusions: A prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage
120. Small chest-tube drainage followed by bleomycin sclerosis for malignant pleural effusions
121. Small bore catheter drainage and sclerotherapy for malignant pleural effusions
122. Pleurodesis with iodized talc for malignant effusions using pigtail catheters
123. Malignant pleural effusions: Treatment with small-borecatheter thoracostomy and talc pleurodesis
124. Talc pleurodesis through small-bore percutaneous tube
125. Clinical efficacy of doxycycline for pleurodesis
126. The efficacy of doxycycline as a pleural sclerosing agent in malignant pleural effusion: A prospective study
127. Bleomycin and tetracycline in malignant pleural effusions: A review
128. Pleurodesis in malignant pleural effusions: A randomized study of tetracycline versus bleomycin
129. Prospective randomized trial of talc slurry vs bleomycin in pleurodesis for symptomatic malignant pleural effusions
130. Sclerotherapy for malignant pleural effusions: Alternatives to tetracycline
131. Sterilization of talc for pleurodesis: Available techniques, efficacy, and cost analysis
132. More on talc sterilization
133. Talc poudrage for malignant pleural effusion
134. Pleurodesis using talc slurry
135. Control of pleural effusions in patients with breast cancer
136. Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion
137. Talc pleurodesis: Experience with 360 patients
138. Thoracoscopic talc poudrage pleurodesis for malignant effusions: A review of 360 cases
139. Talc pleurodesis for the treatment of pneumothorax and pleural effusion
140. Talc slurry pleurodesis: Pleural fluid and histologic analysis
141. Lung function 22-25 years after treatment of idiopathic spontaneous pneumothorax with talc poudrage or simple drainage
142. Effects of pleural talc poudrage on pulmonary function
143. Lung function studies in poudrage treatment of recurrent spontaneous pneumothorax
144. Mortality among talc miners and millers in New York state
145. A survey of the long-term effects of talc and kaolin pleurodesis
146. Respiratory failure due to insufflated talc
147. Respiratory failure following talc pleurodesis
148. Adult respiratory distress syndrome following intrapleural instillation of talc
149. Talc pleurodesis for treating malignant pleural effusions
150. Survival and talc pleurodesis in metastatic pleural carcinoma, revisited: Report of 125 cases
151. Pleural malignancies in pulmonary and critical care medicine
152. The effect of patient positioning on the distribution of tetracycline in the pleural space during pleurodesis
153. A comparison of rotation and non-rotation in tetracycline pleurodesis
154. The management of recurrent malignant pleural effusions: The complementary role of talc pleurodesis and pleuro-pentoneal shunting
155. Parietal pleurectomy for malignant pleural effusion
156. The non-functioning pleuroperitoneal shunt: Revise or replace?
157. Intrapleural chemotherapy without pleurodesis for malignant pleural effusions LCSG 861
158. A comparative trial of LC 9018 plus doxorubicin alone for the treatment of malignant pleural effusion secondary to lung cancer
159. Treatment of malignant pleural effusions with doxorubicin hydrochloride-containing poly(-L-lactic acid) microspheres
160. Intrapleural natural beta interferon in the treatment of malignant pleural effusions
161. Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion
162. Intrapleural immunotherapy with escalating doses of IL-2 in metastatic pleural effusions
163. Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma
164. Intrapleural treatment with gamma-interferon in early stage malignant pleural mesothelioma
165. Intrapleural production of interleukin 6 during mesothelioma and its modulation by gamma-interferon treatment
166. Mesothelioma-like tumours of the pleura: A review of 72 autopsy cases
167. The significance of cytologically negative pleural effusion in bronchogenic carcinoma
168. Isolated pleural effusion in small cell lung carcinoma: Favorable prognosis
169. Lung cancer and ipsilateral pleural effusion
170. Pleuroscopy in clinical evaluation and staging of lung cancer
171. Benign and malignant mesothelioma
172. Natural history and epidemiology of malignant mesothelioma
173. A case report of malignant pleural mesothelioma with long-term disease control after chemotherapy
174. Aspects of histopathological subtype as a prognostic factor in 85 pleural mesotheliomas
175. Diagnosis and management of malignant pleural effusions
176. Chemotherapy in malignant pleural mesothelioma: A review
177. Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma
178. Extrapleural pneumonectomy, chemotherapy and radiotherapy in the treatment of diffuse malignant pleural mesothelioma
179. Intrapleural administration of interleukin 2 in pleural mesothelioma: A phase 1-11 study
180. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy
181. Pleural effusions in breast carcinoma: Analysis of 122 cases
182. The value of cells in the pleural fluid in the differential diagnosis
183. Pleural effusions following supervoltage radiation for breast carcinoma
184. Management of pleural effusions in breast cancer
185. Survival of patients with pleural involvement by breast carcinoma
186. The Nisbet Symposium: Hodgkin's disease. Radiological aspects of the disease
187. Pleural effusion in multiple myeloma
188. Pleural effusions, ascites, pericardial effusions and edema in Hodgkin's disease
189. Pleural effusion in non-Hodgkin's lymphoma
190. Hodgkin's disease of the lung
191. Non-Hodgkin's lymphoma, chronic lymphatic leukaemia, and the lung
192. Characteristics and prognostic value of pleural effusions in non-Hodgkin's lymphomas
193. The management of pleural effusions and chylothorax in lymphoma
194. The cytological presentation of malignant lymphomas and related diseases in effusions
195. Usefulness of chromosome examination in the diagnosis of malignant pleural effusions
196. Pleural effusion complicating intensive mediastinal radiation therapy
197. Chylothorax after mantle field irradiation for Hodgkin's disease
198. Medical thorascopic talc pleurodesis for chylothorax due to lymphoma: A case series
199. Pleuroperitoneal shunts in the management of persistent chylothorax
200. Pleural effusion due to multiple myeloma
201. Pleural effusion in multiple myeloma
202. Pleural immunocytoma with Waldenström's macroglobulinemia
203. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma
204. Clinical protocol. Treatment of advanced mesothelioma with the recombinant adenovirus H5.010RSVTK: A phase I trial (BB-IND 6274)
205. Expression of the urokinase-type plasminogen activator receptor in human malignant mesothelioma cells: Role in tumour cell mitogenesis and proteolysis
206. Regulation of fibrin deposition by malignant mesothelioma
207. A urokinase receptor mRNA binding protein-mRNA interaction regulates receptor expression and function in human pleural mesothelioma cells
208. Post-transcriptional regulation of urokinase receptor gene expression in human lung carcinoma and malignant mesothelioma cells in vitro